Loading search results
FULL REVASC
Sponsor study identifier
interventional
1,542
1 country
1
Study Start
August 8, 2016
Actual (reported)Primary Completion
July 17, 2023
Actual (reported)Study Completion
July 17, 2023
Actual (reported)Background: The best strategy for ST-elevation myocardial infarction (STEMI) patients with multi-vessel disease, who undergo primary percutaneous coronary intervention (PCI) of the infarct-related artery (IRA) in the acute phase with remaining multivessel disease, is still not well established. Current guidelines recommend PCI of only the infarct related artery (IRA). However, recent small scale randomised controlled trials indicate that full revascularization of these non-infarct related arteries during the index procedure is superior to initial conservative treatment. Fractional flow reserve (FFR), a method used to determine ischemia-inducing lesions, has been shown to be superior to angiography-guided PCI in stable angina. Objective and methods: To test the hypothesis that a strategy of systematic complete revascularization with FFR-guided PCI following STEMI/very high risk NSTEMI leads to improved clinical outcomes compared to initial conservative management of non-culprit lesions. The trial is a prospective international multicentre registry-based randomized controlled trial with combined primary endpoint of all-cause mortality, or non-fatal MI, or unplanned revascularization at a minimum follow-up of 2-3 years. The first key secondary endpoint is the combined endpoint of all-cause mortality or myocardial infarction. The second key secondary endpoint is unplanned revascularization. 1542 patients with acute STEMI/very high risk NSTEMI with multi-vessel disease in Sweden, Denmark, Serbia, Finland, Latvia, Australia and New Zealand will be randomized into 2 arms:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 17, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1, 2016
Actual (reported)August 8, 2016
Actual (reported)August 10, 2016
Actual (reported)July 17, 2023
Actual (reported)July 17, 2023
Actual (reported)Combined endpoint of all-cause mortality, or myocardial infarction, or unplanned revascularization.
Combined endpoint of all-cause mortality, or myocardial infarction, or unplanned revascularization during a minimum follow-up of 2-3 years.
Minimum 2-3 years
Combined endpoint of all-cause mortality, or myocardial infarction.
Minimum 2-3 years.
Number of patients with unplanned revascularization (PCI/CABG) of the coronary arteries
Minimum 2-3 years.
Combined end point of all-cause mortality, MI, and unplanned revascularization (PCI/CABG) at a minimum follow-up of 2-3 years in pre-specified subgroups
Minimum 2-3 years.
All-cause mortality
Minimum 2-3 years.
Myocardial infarction (fatal and non-fatal)
Minimum 2-3 years.
Contrast volume
1 month
X-ray duration
1 month
Neurological complications
1 month
Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of \>0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued. Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study.
Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
Initial Conservative management of non-culprit lesions during index hospital admission
Karolinska University Hospital
Stockholm, S-171 76, Sweden
Bohm F, Mogensen B, Engstrom T, Stankovic G, Srdanovic I, Lonborg J, Zwackman S, Hamid M, Kellerth T, Lauermann J, Kajander OA, Andersson J, Linder R, Angeras O, Renlund H, Erglis A, Menon M, Schultz C, Laine M, Held C, Ruck A, Ostlund O, James S; FULL REVASC Trial Investigators. FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1481-1492. doi: 10.1056/NEJMoa2314149. Epub 2024 Apr 8.
Ong P, Martinez Pereyra V, Sechtem U, Bekeredjian R. Management of patients with ST-segment myocardial infarction and multivessel disease: what are the options in 2022? Coron Artery Dis. 2022 Sep 1;33(6):485-489. doi: 10.1097/MCA.0000000000001157. Epub 2022 Jul 11.
Felix Bohm, MD, PhD
Karolinska Institutet
Stefan James, Professor
Uppsala University, Sweden
Andreas Rück, MD, PhD
Karolinska University Hospital
Thomas Engstrøm, MD, PhD
Copenhagen University Hospital, Rigshospitalet
1,542 participants (actual enrollment reported by the registry).
First Submitted
August 1, 2016
First Posted
August 10, 2016
Study Start
August 8, 2016
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Bohm F, Mogensen B, Ostlund O, Engstrom T, Fossum E, Stankovic G, Angeras O, Erglis A, Menon M, Schultz C, Berry C, Liebetrau C, Laine M, Held C, Ruck A, James SK. The Full Revasc (Ffr-gUidance for compLete non-cuLprit REVASCularization) Registry-based randomized clinical trial. Am Heart J. 2021 Nov;241:92-100. doi: 10.1016/j.ahj.2021.07.007. Epub 2021 Jul 24.
Mika Laine, MD, PhD
Helsinki University Hospital, Finland
Andrejs Erglis, Professor
Riga, Latvia
Goran Stankovic, Professor
Belgrade, Serbia
Carl Schultz, Professor
Perth, Australia
Madhav Menon, MD, PhD
Hamilton, New Zealand
Primary Completion
July 17, 2023
Actual (reported)Study Completion
July 17, 2023
Actual (reported)Last Updated
February 16, 2024
Record last verified: 2024-02
Individual participant data will be confidential. Only data on Group level will be presented in scientific publications.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: